Long-term outcome after prophylactic lamivudine treatment of hepatitis B virus reactivation in non-Hodgkin's lymphoma

Jin Seok Kim, Jee Sook Hahn, Sun Young Park, Yuri Kim, In Hae Park, Chun Kyon Lee, June Won Cheong, Seung Tae Lee, Yoo Hong Min

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.

Original languageEnglish
Pages (from-to)78-89
Number of pages12
JournalYonsei medical journal
Volume48
Issue number1
DOIs
Publication statusPublished - 2007 Feb 1

Fingerprint

Lamivudine
Hepatitis B virus
Non-Hodgkin's Lymphoma
Hepatitis B e Antigens
Drug Therapy
Therapeutics
Hepatitis B Surface Antigens
Viral Load
Aspartic Acid
Peripheral Blood Stem Cell Transplantation
Mutation
Chronic Hepatitis B
Methionine
Hepatitis
Tyrosine
Steroids
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Jin Seok ; Hahn, Jee Sook ; Park, Sun Young ; Kim, Yuri ; Park, In Hae ; Lee, Chun Kyon ; Cheong, June Won ; Lee, Seung Tae ; Min, Yoo Hong. / Long-term outcome after prophylactic lamivudine treatment of hepatitis B virus reactivation in non-Hodgkin's lymphoma. In: Yonsei medical journal. 2007 ; Vol. 48, No. 1. pp. 78-89.
@article{bc8499f9c88b46be848568c2e40b882e,
title = "Long-term outcome after prophylactic lamivudine treatment of hepatitis B virus reactivation in non-Hodgkin's lymphoma",
abstract = "Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75{\%}), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25{\%}). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.",
author = "Kim, {Jin Seok} and Hahn, {Jee Sook} and Park, {Sun Young} and Yuri Kim and Park, {In Hae} and Lee, {Chun Kyon} and Cheong, {June Won} and Lee, {Seung Tae} and Min, {Yoo Hong}",
year = "2007",
month = "2",
day = "1",
doi = "10.3349/ymj.2007.48.1.78",
language = "English",
volume = "48",
pages = "78--89",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Long-term outcome after prophylactic lamivudine treatment of hepatitis B virus reactivation in non-Hodgkin's lymphoma. / Kim, Jin Seok; Hahn, Jee Sook; Park, Sun Young; Kim, Yuri; Park, In Hae; Lee, Chun Kyon; Cheong, June Won; Lee, Seung Tae; Min, Yoo Hong.

In: Yonsei medical journal, Vol. 48, No. 1, 01.02.2007, p. 78-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term outcome after prophylactic lamivudine treatment of hepatitis B virus reactivation in non-Hodgkin's lymphoma

AU - Kim, Jin Seok

AU - Hahn, Jee Sook

AU - Park, Sun Young

AU - Kim, Yuri

AU - Park, In Hae

AU - Lee, Chun Kyon

AU - Cheong, June Won

AU - Lee, Seung Tae

AU - Min, Yoo Hong

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.

AB - Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.

UR - http://www.scopus.com/inward/record.url?scp=33947132756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947132756&partnerID=8YFLogxK

U2 - 10.3349/ymj.2007.48.1.78

DO - 10.3349/ymj.2007.48.1.78

M3 - Article

C2 - 17326249

AN - SCOPUS:33947132756

VL - 48

SP - 78

EP - 89

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -